MedPath
NMPA Approval

Indacaterol Acetate and Mometasone Furoate Powder for Inhalation(I)

国药准字HJ20210046

June 18, 2021

Drug Information

茚达特罗莫米松吸入粉雾剂(Ⅰ)

吸入粉雾剂

每粒含醋酸茚达特罗150μg(以 C₂₄H₂₈N₂O₃计)和糠酸莫米松80μg。

化学药品

June 18, 2021

June 17, 2026

Company Information

Applicant Company

Shop 6/207 Pacific Highway St Leonards NSW 2065 Australia

Manufacturing Company

siegfried barbera, s.l.;novartis pharma stein ag

Ronda Santa Maria 158 BARBERA DEL VALLES BARCELONA, 08210 Spain;Chemical Operations Schweiz Schaffhauserstrasse Stein, CH-4332, Switzerland.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

茚达特罗莫米松吸入粉雾剂(Ⅰ) - NMPA 批准文号 | MedPath